SK Biopharmaceuticals Co., Ltd. Stock price

Equities

A326030

KR7326030004

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-02-21 pm EST 5-day change 1st Jan Change
90,900 KRW +0.78% Intraday chart for SK Biopharmaceuticals Co., Ltd. +6.44% -9.46%
Sales 2023 355B 267M Sales 2024 * 489B 368M Capitalization 7,119B 5.35B
Net income 2023 -33B -24.82M Net income 2024 * 32B 24.06M EV / Sales 2023 22.2 x
Net cash position 2023 * 103B 77.82M Net cash position 2024 * 154B 115M EV / Sales 2024 * 14.2 x
P/E ratio 2023 *
-158 x
P/E ratio 2024 *
222 x
Employees 252
Yield 2023 *
-
Yield 2024 *
-
Free-Float 35.73%
More Fundamentals * Assessed data
Dynamic Chart
SK Biopharmaceuticals Swings to Profit in Q4 MT
SK Group Advances Net Zero Transition via Key Renewable Energy Deal MT
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics CI
Sk Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and Moped Molecular Glue Screening Platform At the 20Th Annual Discovery on Target Conference CI
SK Biopharmaceuticals Co., Ltd. acquired remaining 605 stake in ProteoVant Sciences, Inc. from Roivant Sciences Ltd.. CI
South Korean Shares Close Higher on Optimism Over China's One-Year Loan Prime Rate Cut; SK Biopharma Adds 2% MT
SK Biopharmaceuticals Enters Licensing Agreement with Hikma's Middle East Division MT
SK Biopharmaceuticals Continues to Report Losses in Q2 MT
SK Biopharmaceuticals Assembles Board of Prominent Experts to Boost Growth, Innovation CI
SK Biopharmaceuticals Forecasts $1 Billion in US Sales by 2029 MT
SK Biopharmaceuticals Co., Ltd. agreed to acquire 60% interest in ProteoVant Sciences, Inc. from Roivant Sciences Ltd. for $47.5 million. CI
SK Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
SK Biopharmaceuticals Narrows Loss in Q1 MT
SK Biopharmaceuticals Swings to Loss in Q4 MT
SK Biopharmaceuticals' Anti-Epilepsy Treatment Cenobamate Approve for Sale in France MT
More news
1 day+0.78%
1 week+6.44%
Current month-2.26%
1 month-1.09%
3 months+1.68%
6 months+5.45%
Current year-9.46%
More quotes
1 week
85 000.00
Extreme 85000
93 300.00
1 month
84 400.00
Extreme 84400
94 900.00
Current year
84 400.00
Extreme 84400
104 800.00
1 year
57 600.00
Extreme 57600
104 800.00
3 years
50 900.00
Extreme 50900
137 500.00
5 years
50 900.00
Extreme 50900
269 500.00
10 years
50 900.00
Extreme 50900
269 500.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 22-12-31
Corporate Officer/Principal - 22-12-31
Corporate Officer/Principal - 17-03-15
Members of the board TitleAgeSince
Director/Board Member 60 17-03-15
Corporate Officer/Principal - 17-03-15
Director/Board Member - 19-08-26
More insiders
Date Price Change Volume
24-02-22 90,900 +0.78% 182,034
24-02-21 90,200 +1.35% 140,941
24-02-20 89,000 +2.89% 222,313
24-02-19 86,500 +1.29% 98,964
24-02-16 85,400 0.00% 125,524

End-of-day quote Korea S.E., February 21, 2024

More quotes
SK Biopharmaceuticals Co Ltd is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The Company also engages in the new drug development business.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
90,900 KRW
Average target price
105,062 KRW
Spread / Average Target
+15.58%
Consensus
  1. Stock
  2. Equities
  3. Stock SK Biopharmaceuticals Co., Ltd. - Korea S.E.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer